Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor
NEW YORK and LONDON and MUNICH and NEW DELHI, Feb. 11, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global leader in non-invasive cancer diagnostics, announces Dr. Massimo Cristofanilli as Strategic Advisor, reinforcing its commitment to advancing early cancer detection and precision treatment. Dr. Cristofanilli, an expert in circulating tumor cells, biomarkers, and molecular profiling, will collaborate with DCG to develop innovative solutions for early and accurate cancer detection and treatment personalization.
A Visionary Leader in Cancer Research
Dr. Cristofanilli has an esteemed career with over 400 scientific publications on cancer biomarkers, liquid biopsy, and targeted therapies. He is a past President of the International Society of Liquid Biopsy (ISLB).
'It is my pleasure to take up this role,' said Dr. Cristofanilli. 'I look forward to collaborating with the DCG team to drive the development of next-generation cancer diagnostic tests that will form the backbone of transformative technologies to detect and treat cancer.'
Enhancing Cancer Diagnostics and Precision Medicine
This collaboration will strengthen DCG's leadership in molecular and functional tumor profiling and liquid biopsies, particularly in circulating tumor cells (CTCs). Dr. Cristofanilli will work with DCG's research teams to expand biomarker-driven innovations for challenging cancers.
'Dr. Cristofanilli's expertise is invaluable to DCG's vision of pushing onco-diagnostics forward,' said Dr. Darshana Patil, MD, Senior Director – Global Strategy and Medical Affairs, DCG. 'His leadership will help refine strategies for next-generation, safer, and more reliable technologies,' added Mr. Rajan Datar, Chairman and Managing Director, DCG.
About Datar Cancer Genetics
Datar Cancer Genetics is a global oncology research company developing non-invasive technologies for improved cancer detection, treatment, and management. The Company's state-of-the-art cancer research centres in the UK, and India are accredited by the relevant certification such as ISO, UKAS, ILAC, CAP and CLIA. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India.
About Dr. Massimo Cristofanilli
Dr. Cristofanilli is a board-certified medical oncologist specializing in molecular diagnostics, liquid biopsy, and drug development, with a focus on metastatic breast cancer. He is Director of Breast Medical Oncology and Scientific Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. A pioneer in Inflammatory Breast Cancer (IBC), he founded the IBC International Consortium and has co-authored over 400 peer-reviewed publications.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
New IBO Survey Reveals Major Cuts to Lab Budgets Amid NIH Grant Terminations
ARLINGTON, Va., June 10, 2025 /PRNewswire/ -- A new survey conducted by Instrument Business Outlook (IBO) has uncovered significant reductions in laboratory budgets across the U.S. academic and government research landscape, with lab product spending sharply impacted by recent NIH grant terminations. The findings, based on an exclusive IBO survey, shed light on the growing financial uncertainty facing scientific research labs in 2025. The results follow widespread disruptions in NIH funding, with more than 1,500 grants totaling $7.5 billion terminated as of May 20, according to data from Grant Watch. While the exact numbers remain fluid due to inconsistent reporting by federal agencies, the toll is undeniable: R01 research grants—a cornerstone of basic research—have been particularly hard-hit, with 322 grants worth nearly $790 million terminated. "The fallout from NIH funding changes is cascading through the research ecosystem," said Tanya Samazan, Editor-In-Chief. "Our survey shows just how deeply this uncertainty is affecting labs—from basic research to clinical trial infrastructure." Survey Highlights: Budget Cuts Across the Board Conducted by the Science Advisory Board (SAB) between mid- and late May, the survey collected 117 responses from U.S.-based labs, with 88 indicating their labs were impacted by NIH-related funding disruptions. Key findings include: 59% of labs report direct impacts from NIH-related grant or contract terminations, delays, or reductions. 47% report indirect impacts. Among affected labs, nearly 60% have reduced 2025 operating budgets by more than 10%. 51% report capital budget reductions exceeding 10%. When excluding labs that were uncertain or unaffected, the scale becomes even more dramatic: 71% of labs report operating budget cuts of over 10%. 71% report similar reductions in capital budgets. Lab Tools and Consumables Hit Hardest Every category of lab spending has been affected, according to survey data: 80% of labs have reduced their 2025 consumables budgets, making it the most impacted category. 63% have cut software/informatics budgets. 70% have reduced spending on devices under $50,000. Even high-end instrumentation (>$150,000) hasn't been spared, with 62% of labs trimming these budgets. Institutes Most Affected The survey findings align with NIH grant termination data indicating the hardest-hit institutions include: National Institute of Mental Health, with over $400 million in losses. National Institute of General Medical Sciences, which lost the highest number of grants (134). Institutes heavily reliant on lab instruments, including the National Institute of Biomedical Imaging and Bioengineering and the National Human Genome Research Institute. Medical schools and hospitals have borne a significant share of the burden, accounting for 50% of terminated grants and 55% of total terminated NIH dollars. A Shifting Landscape with No Clear Path Forward The rapidly evolving nature of NIH decisions—including ongoing terminations and reinstatements—has created a volatile funding environment. Labs are being forced to make difficult decisions with limited visibility into future funding. About Instrument Business Outlook (IBO)IBO is a leading newsletter providing market intelligence for the analytical instrument industry. Published by Strategic Directions International (SDi), a division of Science and Medicine Group, IBO offers in-depth coverage of technology, business, and market trends affecting the life sciences and lab tools sectors. View original content to download multimedia: SOURCE Instrument Business Outlook
Yahoo
19 minutes ago
- Yahoo
Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025
Full data of Phase 3 REDEFINE 1 and 2 trial results will provide insights on the potential of CagriSema Semaglutide real-world data complements evidence from previous cardiometabolic and kidney outcomes trials Data on pipeline candidate amycretin to underscore Novo Nordisk's scientific efforts to continued innovation in obesity PLAINSBORO, N.J., June 10, 2025 /PRNewswire/ -- Novo Nordisk today announced that new data from its industry-leading cardiometabolic portfolio will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago, June 20 – 23, 2025. A total of 29 abstracts will be presented, including trials investigating the efficacy and safety of CagriSema in people with overweight/obesity (REDEFINE 1) and those with overweight/obesity and type 2 diabetes (REDEFINE 2).1 Further, new data will complement the extensive body of cardiometabolic and kidney evidence for semaglutide in people with type 2 diabetes through analyses of the SOUL, STRIDE and FLOW trials, as well as insights from additional real-world studies in adults with obesity.2-4 "We recognize the complex interplay between cardiovascular and metabolic diseases, including type 2 diabetes and obesity, which require a personalized treatment approach," said Martin Holst Lange, Executive Vice President for Development at Novo Nordisk. "As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease." The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine. Data will also be presented on pipeline candidate amycretin, demonstrating Novo Nordisk's scientific efforts to deliver innovation in cardiometabolic diseases and individualized healthcare solutions.1 On June 22nd, Novo Nordisk will also host an R&D investor event on our metabolic and cardiovascular health portfolio to cover the science and abstracts presented at the congress. The event will be accessible via a live webcast on the Novo Nordisk investor website. Full details of Novo Nordisk abstracts to be presented at ADA 2025. These data for medicines containing semaglutide, CagriSema, amycretin, insulin icodec, and IcoSema are investigational: ADA Scientific Sessions:
Yahoo
25 minutes ago
- Yahoo
Dual Enrollment and Graduate Enrollment Continue Upward Trend at Freed-Hardeman University
Freed-Hardeman University has reached an eight-year high in new graduate enrollment and sustained nearly a decade of growth in dual enrollment, underscoring its ongoing commitment to accessible, high-quality education. HENDERSON, Tenn., June 10, 2025 /PRNewswire-PRWeb/ -- Freed-Hardeman University has achieved an eight-year high in new graduate student enrollment this spring, building on five consecutive semesters of year-over-year growth in graduate education. FHU has also seen nearly a decade of steady expansion in its dual enrollment program, reflecting the university's continued commitment to accessible, high-quality education at every academic level. FHU President David R. Shannon emphasized the impressive reach and versatility of a Freed-Hardeman education. "Whether our students are high schoolers looking to get ahead, undergraduates choosing their future paths, or working professionals wanting to excel in their careers, FHU faculty and staff members go above and beyond to provide the resources that meet the needs of students at every stage," he said. Launched in 2014, the online dual enrollment program allows qualified high school juniors and seniors across the country early access to FHU courses, offering younger students a jumpstart on their post-secondary educational goals. The university currently partners with 19 high school institutions in five states. During the past nine years, enrollment has grown by 545%, increasing from 103 students to 664. Credit hours have similarly climbed—from 542 to 3,529, a 551% increase. "FHU's dual enrollment program continues to be an exciting opportunity for high school students to begin working toward a college degree," said Dr. Jared Gott, assistant dean of Emerging and Innovative Programs. "Beyond the program's growth, we are encouraged by our students' academic performance and the levels of program satisfaction. The dual enrollment program allows students to position themselves for financial, academic and professional flexibility." At the graduate level, FHU offers 16 master's programs, four graduate certificates, and six specialist and doctoral programs. The university has achieved five consecutive semesters of new student growth and three straight years of improved graduate retention. Designed for working professionals, classes are available both online and in person. Currently, graduate students represent more than 14 different states, and the average age of students entering the program is 35. Programs seeing the highest recent growth include the Master of Science in Clinical Mental Health Counseling, Doctor of Behavioral Health, Master of Divinity, and Master of Arts in Teaching. Dr. Trent Adams, assistant dean of Graduate Admissions, noted the collaborative nature of the program's success. "Our five consecutive semesters of year-over-year growth in new graduate students represent the power of meaningful partnerships," he said. "By collaborating with school districts, mental health agencies, universities, ministry networks and others, we've been able to extend the reach and relevance of our programs. We're proud to walk alongside students as they enroll in our programs to prepare for new careers or elevate their current roles. We're honored they trust FHU to help them invest in themselves." The growth of dual enrollment and graduate programs reflects Freed-Hardeman University's commitment to long-term student success. By providing flexible, high quality learning opportunities, FHU equips students at every stage of life to advance their education, achieve their goals and make a meaningful impact in their fields. The mission of Freed-Hardeman University is to help students develop their God-given talents for His glory by empowering them with an education that integrates Christian faith, scholarship and service. With locations in Henderson and Memphis, FHU offers associate, bachelor's, master's, specialist and doctoral degrees. More information is available at Media Contact Dawn Bramblett, Freed-Hardeman University, 731-608-7650, dawn@ View original content to download multimedia: SOURCE Freed-Hardeman University Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
